As of 2025-10-19, the EV/EBITDA ratio of Oramed Pharmaceuticals Inc (ORMP) is -5.89. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ORMP's latest enterprise value is 75.63 mil USD. ORMP's TTM EBITDA according to its financial statements is -12.85 mil USD. Dividing these 2 quantities gives us the above ORMP EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2025-10-17 | -5.89 |
| 2025-10-16 | -6.02 |
| 2025-10-15 | -6.02 |
| 2025-10-14 | -6.30 |
| 2025-10-13 | -6.46 |
| 2025-10-10 | -6.46 |
| 2025-10-09 | -6.33 |
| 2025-10-08 | -6.40 |
| 2025-10-07 | -6.69 |
| 2025-10-06 | -6.59 |
| 2025-10-03 | -6.56 |
| 2025-10-02 | -6.79 |
| 2025-10-01 | -6.91 |
| 2025-09-30 | -7.20 |
| 2025-09-29 | -7.39 |
| 2025-09-26 | -6.46 |
| 2025-09-25 | -6.43 |
| 2025-09-24 | -6.43 |
| 2025-09-23 | -6.72 |
| 2025-09-22 | -6.65 |
| 2025-09-19 | -6.24 |
| 2025-09-18 | -6.56 |
| 2025-09-17 | -6.02 |
| 2025-09-16 | -6.08 |
| 2025-09-15 | -6.18 |
| 2025-09-12 | -6.46 |
| 2025-09-11 | -6.53 |
| 2025-09-10 | -6.21 |
| 2025-09-09 | -6.14 |
| 2025-09-08 | -6.11 |
| 2025-09-05 | -5.89 |
| 2025-09-04 | -5.86 |
| 2025-09-03 | -5.79 |
| 2025-09-02 | -5.63 |
| 2025-08-29 | -5.79 |
| 2025-08-28 | -5.79 |
| 2025-08-27 | -5.82 |
| 2025-08-26 | -5.54 |
| 2025-08-25 | -5.70 |
| 2025-08-22 | -5.60 |
| 2025-08-21 | -5.35 |
| 2025-08-20 | -5.38 |
| 2025-08-19 | -5.35 |
| 2025-08-18 | -5.41 |
| 2025-08-15 | -5.41 |
| 2025-08-14 | -5.54 |
| 2025-08-13 | -5.54 |
| 2025-08-12 | -5.47 |
| 2025-08-11 | -5.44 |
| 2025-08-08 | -5.44 |